Table 2 Association between INAVA expression and clinicopathologic parameters in PTC patients
From: INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression
Clinicopathologic variables (n) | INAVA | P value | |
|---|---|---|---|
Low | High | ||
Age (years) | |||
 < 45 (59) | 32 | 27 | 0.455 |
 ≥ 45 (53) | 25 | 28 |  |
Gender | |||
 Male (23) | 12 | 11 | 0.890 |
 Female (89) | 45 | 44 |  |
TNM stage | |||
 I and II (73) | 44 | 29 | 0.007 |
 III and IV (39) | 13 | 26 |  |
T classification | |||
 T1 and T2 (69) | 40 | 29 | 0.058 |
 T3 and T4 (43) | 17 | 26 |  |
Lymph node metastasis | |||
 No (58) | 37 | 21 | 0.005 |
 Yes (54) | 20 | 34 |  |